Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

Moreira, Fabrício A.; Guimarães, Francisco S.

doi:10.1016/j.ejphar.2005.02.040

Cited by 206Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentForensic Toxicology and Drug Analysis

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

Moreira, Fabrício A., Guimarães, Francisco S.·2005·European Journal of Pharmacology

DOI 10.1016/j.ejphar.2005.02.040

Open this paper in CoChat — free account

Abstract

Cannabidiol is a non-psychotomimetic compound from Cannabis sativa. It is proposed as a possible antipsychotic drug, since it can prevent some psychotomimetic-like effects of Delta9-tetrahydrocannabinol or apomorphine. Therefore, the aim of this work was to test the hypothesis that cannabidiol would inhibit the hyperlocomotion induced by two psychotomimetic drugs, D-amphetamine or ketamine. Male Swiss mice received i.p. injections of haloperidol (0.15-0.6 mg/kg), clozapine (1.25-5 mg/kg) or cannabidiol (15-60 mg/kg) followed by D-amphetamine (5 mg/kg) or ketamine (60 mg/kg). Thirty minutes after the first injection, the distance moved in circular arena was measured during 10 min. In another group of experiments, catalepsy was measured 30 min after haloperidol, clozapine or cannabidiol injections. Cannabidiol, like clozapine but unlike haloperidol, inhibited hyperlocomotion without inducing catalepsy. Moreover, cannabidiol itself, unlike haloperidol and clozapine, did not decrease locomotion. In conclusion, cannabidiol exhibits an antipsychotic-like profile without inducing extrapyramidal-like effects.

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2005.02.040

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

CBD is able to decrease hyperlocomotion and pre-pulse inhibition (PPI) impairment induced by amphetamine in both mice and rats.
“Later, we showed that CBD is also able to decrease hyperlocomotion and pre-pulse inhibition (PPI) impairment induced by amphetamine in both mice and rats (67, 69) (Table 2).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [67]

Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun.
Morgan, J., & Curran, T. (1991) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.14.030191.002225 · Cited by 2,689 · see citing works
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · see citing works
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · see citing works
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
GOFF, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 914 · see citing works
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · see citing works
BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROME
Bach, F. H., Albertini, R., Joo, P., Anderson, J., & Bortin, M. M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92672-x · Cited by 867 · see citing works
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · see citing works
To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test
Lipska, B. K. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00137-8 · Cited by 650 · see citing works
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608 · see citing works
Schizophrenia
Freedman, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035458 · Cited by 593 · see citing works
Marihuana Chemistry
Mechoulam, R. (1970) · Science · doi:10.1126/science.168.3936.1159 · Cited by 494 · see citing works
Neuroleptics increase C-FOS expression in the forebrain: Contrasting effects of haloperidol and clozapine
Robertson, G. S., & Fibiger, H. C. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90054-6 · Cited by 474 · see citing works
Bringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403 · see citing works
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · see citing works
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 339 · see citing works
Chemical Basis of Hashish Activity
Mechoulam, R., Shani, A., Edery, H., & Grunfeld, Y. (1970) · Science · doi:10.1126/science.169.3945.611 · Cited by 331 · see citing works
The catalepsy test: Its ups and downs.
Sanberg, P. R., Bunsey, M. D., Giòrdano, M., et al. (1988) · Behavioral Neuroscience · doi:10.1037//0735-7044.102.5.748 · Cited by 323 · see citing works
The catalepsy test: Its ups and downs.
Sanberg, P. R., Bunsey, M. D., Giòrdano, M., et al. (1988) · Behavioral Neuroscience · doi:10.1037/0735-7044.102.5.748 · Cited by 322 · see citing works
Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity.
Robertson, G. S., Matsumura, H., & Fibiger, H. C. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23800-9 · Cited by 311 · see citing works
Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303 · see citing works
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264 · see citing works
Self-citation
Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.
Strange, P. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01483-2 · Cited by 249 · see citing works
Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists
Thomas, B. F., Gilliam, A. F., Burch, D. F., Roche, M. J., & Seltzman, H. H. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37365-3 · Cited by 242 · see citing works
Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system
Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226 · see citing works
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability
Hoffman, D., & Donovan, H. (1995) · Psychopharmacology · doi:10.1007/bf02246184 · Cited by 224 · see citing works
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton, D. M., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11216-0 · Cited by 216 · see citing works
Network interactions in schizophrenia - therapeutic implications.
Carlsson, A., Waters, N., Waters, S., & Carlsson, M. (2000) · Brain research. Brain research reviews · doi:10.1016/s0165-0173(99)00050-8 · Cited by 192 · see citing works
Effects of cannabidiol in animal models predictive of antipsychotic activity
Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191 · see citing works
New Antipsychotics: Classification, Efficacy, and Adverse Effects
Gerlach, J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.289 · Cited by 183 · see citing works
Complex pharmacology of natural cannabivoids: Evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors
Petitet, F., Jeantaud, B., Reibaud, M., Impérato, A., & Dubroeucq, M. C. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00238-0 · Cited by 180 · see citing works
CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES
Rottanburg, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91270-3 · Cited by 179 · see citing works
Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice
Irifune, M., Shimizu, T., & Nomoto, M. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90571-i · Cited by 162 · see citing works
Neurobiology of schizophrenia
Egan, M. F., & Weinberger, D. R. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80092-x · Cited by 156 · see citing works
Stimulant Psychosis: Symptom Profile and Acute Clinical Course
Harris, D. S., & Batki, S. L. (2000) · American Journal on Addictions · doi:10.1080/10550490050172209 · Cited by 153 · see citing works
Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents
Carlini, E. A., Leite, J. R., Tannhauser, M., & Berardi, A. C. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10660.x · Cited by 125 · see citing works
The changing roles and targets for animal models of schizophrenia
Kilts, C. D. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01286-0 · Cited by 116 · see citing works
Angiotensin, LDL peroxidation and atherosclerosis
Keidar, S. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00014-9 · Cited by 93 · see citing works
Hypnoticlike effects of cannabidiol in the rat
Monti, J. M. (1977) · Psychopharmacology · doi:10.1007/bf00497858 · Cited by 84 · see citing works
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
Guimaraes, V. H. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.015 · Cited by 75 · see citing works
Motor and mental aspects of acute extrapyramidal syndromes
Casey, D. E. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05826.x · Cited by 69 · see citing works
Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man
Hunt, C. A., Jones, R. T., Herning, R. I., & Bachman, J. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059266 · Cited by 50 · see citing works
Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination.
Zuardi, A. W., & Karniol, I. G. (1983) · PubMed · Cited by 38 · see citing works
Effects of multiple pretreatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine
Riffee, W. H., & Wilcox, R. E. (1985) · Psychopharmacology · doi:10.1007/bf00427330 · Cited by 27 · see citing works
Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects
Pretorius, J. L., Phillips, M. A., Langley, R. W., Szabadi, E., & Bradshaw, C. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01448.x · Cited by 25 · see citing works
Is it possible to model psychotic states in animals?
Iversen, S. D. (1987) · Journal of Psychopharmacology · doi:10.1177/026988118700100303 · Cited by 21 · see citing works
Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L.
Formukong, E. A., EVANS, A. T., & Evans, F. J. (1988) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1988.tb05198.x · Cited by 21 · see citing works
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
Guimaraes, V. H. (2004) · Life Sciences · doi:10.1016/s0024-3205(04)00291-7 · Cited by 10 · see citing works

Flagged first, then by citations

Sorted by citations

Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Self-citation
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · see citing works
Self-citation
Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT<sub>1A</sub>receptors
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366 · see citing works
Self-citation
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360 · see citing works
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Self-citation
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222 · see citing works
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · see citing works
Self-citation
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192 · see citing works
Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
Resstel, L. B. M., Joca, S. R. L., Moreira, F. A., Corrêa, F. M. A., & Guimarães, F. S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.016 · Cited by 182 · see citing works
Self-citation
Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Self-citation
Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146 · see citing works
Self-citation
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works
Self-citation
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · see citing works
Self-citation
Prohedonic effect of cannabidiol in a rat model of depression
Shoval, G., Shbiro, L., Hershkovitz, L., Hazut, N., Zalsman, G., Mechoulam, R., & Weller, A. (2016) · Neuropsychobiology · doi:10.1159/000443890 · Cited by 110 · see citing works
Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release
Gobira, P. H., Vilela, L. R., Gonçalves, B. D. C., Santos, R. P. M., de Oliveira, A. C., Vieira, L. B., Aguiar, D. C., Crippa, J. A., & Moreira, F. A. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.08.007 · Cited by 89 · see citing works
Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89 · see citing works
Self-citation
Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala
Réus, G. Z., Stringari, R. B., Ribeiro, K. F., Luft, T., Abelaira, H. M., Fries, G. R., Aguiar, B. W., Kapczinski, F., Hallak, J. E., Zuardi, A. W., et al. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00579.x · Cited by 86 · see citing works
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83 · see citing works
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine
Pedrazzi, J. F. C., Issy, A. C., Gomes, F. V., Guimarães, F. S., & Del-Bel, E. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3945-7 · Cited by 76 · see citing works
Self-citation
Effects of Adolescent THC Exposure on the Prefrontal GABAergic System: Implications for Schizophrenia-Related Psychopathology
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62 · see citing works

Authors: Moreira, F. A., & Guimarães, F. S.
Affiliations: Universidade de São Paulo (BR)
Corresponding author: Moreira, Fabrício A.
ORCID: Moreira, Fabrício A.
Guimarães, Francisco S.
Venue: European Journal of Pharmacology
Publisher: Elsevier BV
Published: 2005-04
Volume: 512
Issue: 2-3
Pages: 199-205
ISSN: 0014-2999 (ISSN-L)
DOI: 10.1016/j.ejphar.2005.02.040
OpenAlex: W1998021006
Cited by: 206
References: 48
Citations by year: 2026: 5 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 18 · 2021: 14 · 2020: 17 · 2019: 11 · 2018: 15 · 2017: 15 · 2016: 16 · 2015: 10 · 2014: 6 · 2013: 5 · 2012: 14
FWCI: 3.39
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Journal of Pharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Topics: Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords: cannabidiol, psychotomimetic drugs, hyperlocomotion, antipsychotic activity, catalepsy, d-amphetamine, ketamine, haloperidol, clozapine, extrapyramidal symptoms, psychostimulants, Cannabis sativa
MeSH terms: Analysis of Variance, Animals, Behavior, Animal, Cannabidiol, Clozapine, Dextroamphetamine, Haloperidol, Injections, Intraperitoneal, Ketamine, Locomotion, Male, Sympathomimetics, Time Factors, Antipsychotic Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks